Close Menu

NEW YORK – Belgian molecular diagnostics firm Biocartis said on Tuesday it has signed a license, development, and commercialization agreement with startup GeneproDx to develop GeneproDx's ThyroidPrint on Biocartis' Idylla platform, as well as a separate agreement with Endpoint Health to develop and commercialize a novel companion diagnostic (CDx) test on the Idylla instrument.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.